Mitochondrial Adaptations in Skeletal Muscle Following Incretin‐Based Therapies: In Vitro
Journal of Cachexia, Sarcopenia and Muscle · 2026
DOI: 10.1002/jcsm.70254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2026. Verfasst von Victoria Old und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Sciences, College of Life Sciences, University of Leicester, Leicester, UK. Hauptthemen laut MEDLINE: Incretins, Muscle, Skeletal, Mitochondria, Adaptation, Physiological. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre (BRC).
Abstract (Originalsprache)
Background
Incretin‐based therapies such as glucagon‐like peptide‐1 receptor agonists (GLP‐1Ras), dual GLP‐1/GIP agonists and amylin analogues have demonstrated significant weight loss benefits. However, their impact on skeletal muscle mitochondrial function, particularly under metabolic stress, remains unclear. This study aimed to investigate the effects of semaglutide (GLP‐1RA), tirzepatide (dual GLP‐1/GIP agonist) and cagrilintide (amylin analogue) on mitochondrial function in C2C12 skeletal muscle myotubes under both healthy and lipotoxic (palmitic acid‐treated) conditions.
Methods
Differentiated C2C12 myotubes were treated with doses of each drug for 48 h and 5 days. Mitochondrial respiration was assessed using the Seahorse XFp analyser, mitochondrial DNA (mtDNA) copy number and oxidative phosphorylation (OXPHOS) complex protein expression were measured by qPCR and western blotting. Key findings were repeated in primary human skeletal muscle cells.
Results
Palmitic acid (PA) significantly impaired mitochondrial function, reducing basal oxygen consumption rate (OCR) by 22% ( p = 0.0056) and ATP production by 25% ( p = 0.0022). In healthy myotubes, semaglutide and cagrilintide transiently reduced basal respiration (↓21%–28%, p < 0.05) and ATP production (↓24%–31%, p < 0.01) at 48 h, along with reductions in Complexes I, III and IV protein expression, all of which resolved by 5 days. Tirzepatide significantly increased maximal respiration (↑20%–25%, p < 0.005) and spare respiratory capacity (↑22%–30%, p < 0.005) after 5 days. In PA‐treated myotubes, semaglutide and cagrilintide acutely worsened mitochondrial impairment (↓ATP production by ~20%–25%, p < 0.01), but these effects resolved by Day 5. Tirzepatide initially suppressed mitochondrial function (↓ATP production, p = 0.0087) but reversed these effects by Day 5, significantly improving ATP production (↑27%–30%, p < 0.005), basal respiration (↑20%, p = 0.0152), and coupling efficiency. mtDNA content remained unchanged across all conditions. Similar responses were noted in human myotubes, with a transient reduction in respiration for semaglutide and cagrilintide (↓30%–62%, p < 0.05) at 48 h and a significant improvement in maximal respiration for tirzepatide at 5 days (↑42%–52%, p = 0.0022).
Conclusion
Incretin‐based therapies exert distinct, time and dose‐dependent effects on skeletal muscle mitochondrial function. Tirzepatide promoted sustained improvements in mitochondrial respiration under both healthy and lipotoxic conditions, indicating potential benefits for maintaining skeletal muscle bioenergetic function. These findings underscore the need for further mechanistic studies and suggest that tirzepatide may have the potential to support skeletal muscle health in metabolic disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Sciences, College of Life Sciences, University of Leicester, Leicester, UK.
- NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
- Diabetes Research Centre, University of Leicester, Leicester, UK.
- Division of Respiratory Sciences, College of Life Sciences, University of Leicester, Leicester, UK.
- Leicester Orthopaedics, University Hospitals of Leicester, Leicester, UK.
- Division of Cancer Studies, University of Leicester, Leicester, UK.
ORCID-Profile: Victoria Old
Förderung
- National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre (BRC)
Zitieren
APA
Old, V., Davies, M., Denniff, M., Choudhary, P., Eastley, N., Ashford, R. U., & Watson, E. (2026). Mitochondrial Adaptations in Skeletal Muscle Following Incretin‐Based Therapies: In Vitro. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.70254
Vancouver
Old V, Davies M, Denniff M, Choudhary P, Eastley N, Ashford RU, et al. Mitochondrial Adaptations in Skeletal Muscle Following Incretin‐Based Therapies: In Vitro. Journal of Cachexia, Sarcopenia and Muscle. 2026. doi:10.1002/jcsm.70254
BibTeX
@article{Old2026,
author = {Old, Victoria and Davies, Melanie and Denniff, Matthew and Choudhary, Pratik and Eastley, Nicholas and Ashford, Robert U and Watson, Emma},
title = {Mitochondrial Adaptations in Skeletal Muscle Following Incretin‐Based Therapies: In Vitro},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2026},
doi = {10.1002/jcsm.70254}
}
EUVIMED